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Abstract
Computational methods for target prediction, based on molecular similarity and network-based approaches, machine
learning, docking and others, have evolved as valuable and powerful tools to aid the challenging task of mode of action
identification for bioactive small molecules such as drugs and drug-like compounds. Critical to discerning the scope and
limitations of a target prediction method is understanding how its performance was evaluated and reported. Ideally,
large-scale prospective experiments are conducted to validate the performance of a model; however, this expensive and
time-consuming endeavor is often not feasible. Therefore, to estimate the predictive power of a method, statistical
validation based on retrospective knowledge is commonly used. There are multiple statistical validation techniques that
vary in rigor. In this review we discuss the validation strategies employed, highlighting the usefulness and constraints of the
validation schemes and metrics that are employed to measure and describe performance. We address the limitations of
measuring only generalized performance, given that the underlying bioactivity and structural data are biased towards
certain small-molecule scaffolds and target families, and suggest additional aspects of performance to consider in order to
produce more detailed and realistic estimates of predictive power. Finally, we describe the validation strategies that were
employed by some of the most thoroughly validated and accessible target prediction methods.
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Introduction
Fueled by the growing amount of chemical and biological data,
the availability of powerful phenotypic screening technologies
[1], and a shift in small-molecule drug discovery from the ‘one
drug one target’ paradigm to ‘polypharmacology’ [2–5], in silico
methods for the prediction of the biomacromolecular targets
of small molecules have become one of the most intensely
researched areas of cheminformatics in recent years. These
methods are useful not only for the discovery of new medicines
but also in the repositioning of existing approved drugs [6–9].
Target prediction methods are typically pair-input problems, in
that they classify a query compound and a biomacromolecule
pair as an interacting (positive) or a non-interacting (negative)
pair. One categorization of target prediction methods, based on
the types of data used, classifies methods into three overarching
approaches: ligand-based, structure-based and chemogenomic
approaches [10, 11]. Ligand-based approaches make predictions
based on the similarity principle, which states that similar
ligands (in the context of this review, small molecules) are likely
to have similar targets. These methods typically make use of







niversitetsbiblioteket i Bergen user on 11 February 2020
2 Mathai et al.
the physicochemical properties of small molecules. They do
not rely on structural information on biomacromolecules.
Their applicability domain is limited primarily by the available
chemical and biological data. Structure-based approaches, such
as ligand docking, use structural data on biomacromolecules
as the main source of information to make predictions. They
are generally more computationally expensive than ligand-
based methods, and their primary limitations are defined by the
availability of relevant target structures and accuracy of scoring
functions. Chemogenomics approaches (or proteochemometric
approaches) are defined here as methods that combine infor-
mation from both ligands and targets to make their predictions
[10–12].
There are several publications discussing techniques that can
be used in validating target prediction models [13–20]. However,
among the many recently published reviews on in silico target
prediction, only few include a discussion of validation strate-
gies [6, 10, 11, 21–26]. With this review we aim to provide a
comprehensive reference of strategies for the validation of target
prediction models. The review begins with a discussion of data
partitioning schemes that are used to train and test models to
measure their performance, highlighting their appropriateness
and limitations. This is followed by an analysis of the met-
rics that are used to measure this performance and of estab-
lished benchmark data sets. Building up on these components,
we point out strategies to obtain more realistic estimates of
the performance of target prediction models that account for
the biases present in the underlying reference data. Finally,
we describe the validation strategies that were employed by
some of the most thoroughly validated and accessible target
prediction methods.
Strategies for validating target prediction
methods
Validation primarily serves two purposes: the selection of an
optimal model and the evaluation of its generalized predictive
performance [13, 14]. Model selection is commonly a result of
an iterative model building process, during which models based
on various algorithms and parameters are built on a training
set and validated on a testing set. This validation procedure is
generally referred to as internal validation. While often used
as the sole means to report on the performance of models,
internal validation is insufficient to determine the predictive
performance as the iterative modeling procedure may introduce
a bias toward the properties of the testing data and hence
result in an overestimation of model performance. Data that
are blinded to the model development process should therefore
be used, in a process known as external validation, to obtain a
more realistic representation of generalized performance [13].
As part of an external validation process, the training set may
be further divided into a construction set (data used to train
and parameterize the model) and a validation set (data used for
the internal validation to optimize the model), while the testing
set is held back for performance assessment [13]. With data in
place to train and test the model, the metrics used to measure
the performance during the testing need to be considered next.
The choice of how a method was validated (that is the data
partitioning schemes used for the validation) and how its perfor-
mance was measured (the metrics used) are therefore essential
in understanding the reported performance.
Data-partitioning schemes
In the simplest case, models can be trained on one set of data and
tested on another set created by random selection (Figure 1A).
Such a single train–test split procedure is only effective if the
training and testing sets are sufficiently large, diverse and rep-
resentative of the parameter space [13, 14, 20]. However, as the
limited amount of available data usually does not allow for large
testing sets, the resulting test statistics may, to some extent, be
an artifact of how the data were split and not an indicator of
generalized performance [13, 14, 16, 18, 25]. Instead of random
selection, a single split of the data into a training and a testing
sets may alternatively be prepared using a time-split approach,
where the model is trained on data compiled before a given
date and tested on data generated later (Figure 1B). The time-
split approach simulates a real-world scenario where a finalized
model is put to use and new interactions are predicted [17].
Martin et al. [27] proposed a ‘realistic split’ approach, where
compounds are clustered based on chemical similarity to mirror
the exploration of new chemical scaffolds over time. In the
realistic split approach, the larger compound clusters form the
training set (∼75% of the total number of compounds), while the
remaining smaller clusters and singletons (∼25%) are reserved
for the testing set. The authors showed that when predicting
activities of high throughput screens, a single 75:25 train–test
split reported over-optimistic performance results when the
split was created using a random sampling (as the compounds
in the testing set were similar to the training set). In contrast,
their sampling approach provided more realistic performance
estimates.
To get a more robust estimate of how a model generalizes,
cross-validation (CV) schemes have emerged, which partition
the data in multiple ways to increase the variation in the training
and testing data and to reduce the influence of how the data is
split on the resulting testing statistics. A simple CV procedure is
the n-fold CV, which involves randomly partitioning the data
into n partitions and iteratively selecting each partition as
the testing data while training the model on the remaining
partitions (Figure 1C). The result is n models and n testing
statistics, the latter of which are then averaged to give a more
realistic estimate of a model’s performance [15, 19]. When n is
equal to the number of observations, the scheme is known as
the leave-one-out CV (LOOCV), with each observation playing
the role of the testing set once. LOOCV is known to produce
over-optimistic estimates of performance in the current context
as there is a high likelihood of finding similarity between the
testing molecule and the training set [13]. Therefore, typically
a 5- or 10-fold CV scheme is chosen where the observations
are divided into 5 or 10 folds, respectively. The folds for an n-
fold CV are often created through random sampling. Pair-input
prediction methods however are known to perform better when
the tested pairs contain small-molecule or target components
that are present in the training data, as such randomly generated
folds for validation may produce over-optimistic performance
results [16, 18, 25]. Alternative sampling methods, like stratified
sampling, aim to address this issue by constructing folds with
desired representations. For stratified sampling, data are first
divided into the different output strata (positive or negative
interactions for example) and are then randomly selected from
the strata so that the desired ratio of observations is represented
in the folds [14]. The folds for a CV performance assessment may
also be designed to ensure that all interaction pairs involving
a particular compound, compound cluster (i.e. structurally
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Figure 1. Illustrations of example data partitioning schemes: (A) a single train–test split, (B) a single train–test split of chronological data, (C) a 5-fold CV scheme, (D)
a single train–test split into construction and validation sets for internal validation and an external testing set for external validation, (E) a 4-fold CV scheme used for
internal validation with a testing set reserved for external validation and (F) a nested CV scheme with a 2-fold loop for internal validation and a 3-fold loop for external
validation.
molecule–target pairs (Figure 2C) are assigned to the same fold.
These types of schemes are useful to estimate the accuracy
of a method with compounds or targets with limited prior
knowledge [25]. As schemes with such designed folds are likely
to have fewer or no similar components between the training
and testing data, the performance will be lower than that
measured with a standard n-fold CV [16, 18, 25]. In order to
give a more thorough estimation of predictive performance, it is
therefore recommended that the results obtained from standard
n-fold CV are compared to those obtained from more challenging
designed-fold testing scenarios [11, 18, 25].
Most computational approaches require parametrization (e.g.
the value of k in a k-nearest neighbour model) via iterative
optimization, during which different values of the parameters
are explored so as to minimize the prediction error. The repeated
use of the identical training and testing sets from a single train–
test split for this optimization procedure is likely to result in
selection bias. That is, the optimized models may be biased
towards the properties of the specific testing data [13, 14]. In
cases where CV is used not only to estimate the performance
of a model but also to determine the best parameters for the
final model, the CV is first repeated over the different values
of the parameters so as to minimize the CV error, and the
parameters with the lowest validation error rates are selected for
the final optimal model [14, 15]. Due to the limitations of data
utilized for the development of target prediction models (such
as implicit biases, data imbalance and incomplete interaction
knowledge), the performance of a model determined through
internal n-fold CV is often over-optimistic because of selection
bias [18, 25]. Therefore, the performance results of this internal
validation should not be considered as a rigorous estimate of the
performance of the selected model. Instead, external validation
should be used to evaluate the performance of the method once
the model has been selected [14]. However, using a single testing
set reserved for external validation (Figure 1D and E) may still
produce performance statistics that are not reflective of the
generalized performance but are an artifact of the testing and
training split and requires the testing set to be withheld from
the model [13].
Nested CV has consequently emerged as a scheme to per-
form external CV and better estimate unbiased performance
(Figure 1F) [13–15]. In nested CV, two CV loops are run: an inner
‘internal validation’ CV loop is used for model selection and
parameter optimization, and an outer ‘external validation’ loop
is used for model evaluation. In the inner loop, models are
trained using construction data and tested using validation data
over all unique parameter values. The parameters that produced
the lowest internal CV error are then used to build models for
the external CV loop, where models are trained on the training
set and tested on the testing set. As the testing set has remained
independent of the parameter selection process, the external CV
errors, often presented as an average error, are a more realistic
estimate of the generalized error of the model [13–15]. It is
important to note that with each iteration of the outer loop,
the combination of parameters may be different due to the
nature of the data in the internal loop that was used to optimize
them. Nested CV does however provide the best estimate of
performance [11, 14].
Often, as is the case with all the validation schemes
described, even when using the data in the testing set for
external validation, a final model, with parameters unchanged,
is trained on the full data. The performance measures therefore
do not evaluate this final model but the process of building the
model. These measurements are dependent on how the data are
split into the training and testing sets [13–15]. Repeated CV and
repeated nested CV, to allow for data variance by resampling
the folds over each repetition, have thus been recommended
as a means of converging on true performance [14]. Repeated
validation, commonly known as bootstrapping, is resampling the
training and testing sets and repeatedly calculating performance
metrics many times over. This iterative process allows for the
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Figure 2. Examples of CV-testing folds designed to have (A) all data points involving specific queries within 1-fold (points inside the purple box), (B) all data points
involving specific targets within 1-fold (points inside the purple box) and (C) all data points involving the components of query compounds–target pairs within one
testing fold (points inside the purple boxes). The data points covered by the blue boxes are omitted from both training and testing data during the CV round involving
the purple boxed data as the testing set, and the remaining data points are used as the training set. Interacting pairs are shown in green while (putative) non-interacting
pairs are shown in white (adapted from Pahikkala et al. [25]).
performance metrics. Krstajic et al. [14] propose a repeated
nested CV scheme, where the internal and external validation
loops each have 50 repetitions, and the lowest and highest error
metric, in addition to the average error metric, are reported
to show the variance in the method’s performance. They
recommend using random n-fold CV for the internal loop and
stratified CV for the external loop when using repeated nested
CV to develop and evaluate a model [14].
In addition to reporting statistical metrics generated from the
above validation schemes, illustrative case studies are also often
reported to highlight the performance of a method. However,
reporting on just a few case studies is not a sufficiently rigorous
approach to determine a model’s performance [26]. Ideally, large-
scale experimental studies would need to be conducted that
allow not only thorough validation but also a demonstration of
a method’s potential impact. However, due to cost, such large-
scale studies are generally not carried out.
Performance metrics
In its most basic form, target prediction can be regarded as
a binary classification problem: a small molecule either inter-
acts with a biomacromolecule (a positive interaction) or it does
not (a negative interaction). Based on this premise, a common
evaluation technique is to complete the confusion matrix. The
confusion matrix shows how the predictions made by a method
on a testing data set (in the current context, data on small
molecules) compare to the known recorded interactions of these
compounds. A two-class confusion matrix consists of a set of
four tallies of the prediction results: the number of true-positive
(TP), true-negative (TN), false-positive (FP) and false-negative
(FN) predictions (Figure 3A). Metrics to describe the performance
of a method are then calculated using these entries. Importantly,
the FP predictions may in fact include undiscovered or unre-
ported interactions and may therefore be more precisely referred
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Figure 3. (A) A binary classification confusion matrix with the four categories of prediction (FPs may include putative false positives); (B) ROC curves: the closer the
curves are to the top left-hand corner, the better. AUC values alone may be deceptive as a lack of correct early predictions may be offset by an increased number of
correct predictions later, leading to high AUC values. This scenario is shown by the green and purple curves. (C) Precision-recall curve: the closer the curve is to the top
right corner, the better the model’s performance.
not account for this kind of missing data, and it is therefore
more appropriate to consider this component as potential FP
predictions.
Two simple measures calculated from the confusion matrix
are the model’s sensitivity (SE) and specificity (SP). SE (also recall
or TP rate) quantifies the model’s ability to detect positive inter-
actions and is the fraction of how many of the known positive
interactions are identified by the target prediction method
SE = TP
TP + FN (1)
SP, or TN rate, quantifies the model’s ability to detect negative
interactions and is the fraction of how many known, or assumed,
negative interactions are identified by the prediction method
SP = TN
TN + FP (2)
Precision (PR), or positive predictive value, quantifies how
many of the predicted interactions are known interactions for
a compound or a set of compounds
PR = TP
TP + FP (3)
Accuracy (ACC) is a basic metric of the overall performance
of binary classifiers that quantifies the proportion of correct
predictions
ACC = TP + TN
TP + TN + FP + FN (4)
A limitation of this metric is that it does not account for data
set imbalance, which is a ubiquitous issue in target prediction,
where data are often made up of a small number of recorded
ligand–target interactions (positive class) and a large number of
observed or assumed non-interactions (negative class). In this
context, a target prediction method that correctly predicts most
non-interactions but fails to identify known positive interactions
would obtain high ACC values, despite its inability to correctly
identify the targets of small molecules [28].
A metric that does consider the proportion of all classes
in the confusion matrix and therefore addresses the issue of
imbalanced data is the Matthews Correlation Coefficient (MCC).
The MCC quantifies the correlation between the predictions and
their true value
MCC = (TP · TN) − (FP · FN)√
(TP + FP) · (TP + FN) · (TN + FP) · (TN + FN) (5)
MCC values range from −1 to +1, with +1 indicating perfect
prediction, 0 a prediction as good as random and −1 a prediction
that is in total disagreement with the measured data. Although
the MCC is regarded as one of the most robust measures of
the quality of binary classification, it is rarely used in target
prediction. In the special case when a model predicts very few
FPs and very few TPs at the same time, the MCC value will be
deceptively high [29].
Other correlation metrics, such as Cohen’s kappa (κ) are
sometimes used to measure the performance of a classifier.
Cohen’s kappa measures the similarity between two sets of
classifications (in this case, the predicted classes and the known
classes for interactions). Kappa quantifies how much better or
worse a classifier is compared to random chance [30–32].
All metrics discussed so far aim at quantifying the ability of
classifiers to discriminate interacting from non-interacting pairs
of small molecules and biomacromolecules. However, rather
than only predicting categories, most target prediction models
return a score or probability that is used to rank predicted
(non-) interactions. The ability of a target prediction method to
recognize interacting pairs of ligands and targets and to rank
them early in the hit list (‘early recognition’) is a key parameter
for the goodness and value of such models. A straightforward
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which quantifies the percentage of compounds for which a
defined number of known interactions is ranked among the top-
k positions. Statements such as ‘for X% of all tested molecules, at
least one known target was ranked among the top k targets’ are
used to report performance. Note that the top-k metric obviously
depends on an arbitrary cut-off (the k value) and the number of
targets considered for ranking, and it does not account for the
statistical likelihood of random pick [33].
The receiver operating characteristic (ROC) curve is used to
determine early enrichment, without an earliness cut-off. The
ROC curve is an easily interpretable plot of the TP rate (SE) on the
y-axis versus the FP rate (1-SP) on the x-axis, and it is drawn by
calculating the cumulative positives and negatives as one moves
down a rank-ordered list (Figure 3B) [34]. The closer a ROC curve
approaches the top left corner of the graph, the better the rank-
ordered list is, since TPs are identified early on, achieving early
enrichment. A ROC curve that approaches the diagonal repre-
sents the random classification of small molecule and target
pairs. Parts of the ROC curve located below the diagonal indicate
a performance that is worse than random ranking.
The ROC curve considers both the correctly classified positive
values (SE on the y-axis has TP in the numerator) and the
correctly classified negative values (1-SP has TN in the denom-
inator) and is therefore a good measure for balanced data sets
[28, 35]. In contrast, the precision-recall curve plots PR (which
has TP in the numerator) on the y-axis versus recall (which
also has TP in the denominator) on the x-axis and is therefore
ideal at visualizing how well positives appear at the top of
the ranking, particularly when the data set has an imbalanced
distribution between positives and negatives (Figure 3C) [28].
Unlike the ROC curve, the closer the precision-recall curve is to
the top right edge, the better. The random classification of small
molecule and target pairs results in a precision-recall curve that
approaches the straight line, where PR is equal to the fraction
of positives in the data set. Parts of the curve located below this
line indicate a performance that is worse than random ranking.
The goodness of a classifier, as reflected by ROC and
precision-recall curves (and others), can, in part, be quantified by
the area under the curve (AUC). AUC values are bound between
1, for ideal models, and 0, for models that make predictions
that are entirely the opposite of the recorded results. To draw
conclusions about a model’s early recognition ability, both AUC
values and the original curve need to be considered, as models
that perform differently with respect to early enrichment may
have the same AUC since a lack of early recognitions may be
offset by later recognitions (Figure 3B) [36, 37].
As the AUC metrics are not sensitive to early recognition,
the robust initial enhancement (RIE) was developed as a single
parameterized metric based on the enrichment factor (which is
the factor by which known interactions are ranked more often











The RIE uses a decreasing exponential weight to calculate
how much better a ranked list of interactions is compared with
the list with random distribution of the positive and negative
targets [38, 39]. The RIE value is dependent on the early cut-off
exponential parameter (α) and the ratio of positive interactions
in the list, the product of which is the exponent component of
the metric. RIE values therefore cannot be compared, unless the
same cut-off and proportion of actives are present, making it
harder to compare different methods [34, 39].
The Boltzmann-enhanced discrimination of ROC (BEDROC)
metric, developed by Truchon et al. [34] for easier comparison,
is the RIE metric scaled between 0 and 1, with 1 implying perfect
prediction
BEDROC (α) = RIE (α) − RIEmin (α)
RIEmax (α) − RIEmin (α) (7)
A BEDROC value of 0.5 is when the observed cumulative
distribution function (the cumulative number of actives versus
the number of predictions in a rank-ordered list) has the same
shape as the cumulative distribution function exponentially
parameterized by the α parameter. This allows BEDROC scores
with the same α parameter to be compared. The BEDROC metric
is therefore more useful in discriminating a method’s early
recognition capabilities than an AUC due to the exponential
weights and allows for easier comparison than the RIE metric
[34, 39].
Benchmark data sets for target prediction
Benchmark data sets can be useful for the comparative assess-
ment of target prediction approaches. However, due to the com-
plexities involved in compiling high-quality representative data
sets, only few have been reported to date. One of the more widely
used [22, 40, 41] benchmark data sets for target prediction is
the Yamanashi data set [42], which was compiled from differ-
ent sources and comprises 5127 drug–target interactions of 932
drugs and 989 targets for G protein-coupled receptors (GPCRs),
ion channels, enzymes and nuclear receptors. Koutsoukas et al.
[43] published a benchmark data set consisting of ∼100 k com-
pounds compiled from the ChEMBL database [44] used to com-
pare the performance of different machine-learning algorithms
[43]. Peón et al. [45] compiled two benchmarking data sets for
their comparative study of ligand-centric methods for target pre-
diction, one with 183 k active compounds with activities (EC50,
Ki, Kd or IC50) below 10 μm and one with 147 k active compounds
with activities below 1 μm. The data set used for externally
testing SwissTargetPrediction has been made available for use
as a benchmark [46]. Most recently, Wang and Kurgan [47] com-
piled and curated a data set from several different databases,
consisting of 449 compounds, 1469 targets and 34 k interactions.
One of a very few sources offering a complete data matrix of
compounds tested against an array of different proteins is the
kinase data set published by Davis et al. [48], which comprises
72 diverse kinase inhibitors measured against 442 kinases and
was suggested by Pahikkala et al. [25] as a high-quality data set
for testing target prediction methods. Two benchmark data sets
specifically designed for testing structure-based methods have
also been reported [49].
Strategies for obtaining more realistic
estimates of model performance
Rigorous validation schemes, involving external validation,
in combination with information-rich performance metrics,
quantify how well a method has generalized. However, the
data employed for target prediction models are usually heavily
biased. In opposition to reality, for example, chemical databases
commonly have an overrepresentation of known actives
compared to known inactives [10, 24, 26]. Established drug
targets are much better represented by the available chemical,
structural and biological data than other biomacromolecules
[11, 50]. Additionally, the synthesizability of compounds and







niversitetsbiblioteket i Bergen user on 11 February 2020
Validation strategies for target prediction methods 7
series of compounds lead to significant biases in the represented
scaffolds [11, 51]. These biases are a natural result of the
drug-development environment and lead to concentrations of
information on certain targets and scaffolds.
Some targets are more challenging to predict than others due
to the specific properties of individual targets or the structural
and functional relationships between the biomacromolecules
covered by a target prediction model. For example, due to its
large and malleable ligand-binding site and no clear pharma-
cophoric requirements, cytochrome P450 (CYP) 3A4 binds to a
broad variety of ligands [52, 53]. These properties mean that,
despite the availability of a substantial body of structural, chem-
ical and biological data, CYP3A4 is a particularly challenging
target to address for both ligand and structure-based methods
[54]. It is also much more difficult for target prediction meth-
ods to discriminate small-molecule activity among structurally
and/or functionally related biomacromolecules. That is, it will be
more challenging to correctly predict a protein kinase inhibitor’s
selectivity profile for kinases than it is to understand whether
the compound will also bind to a certain GPCR. For all these
reasons, the number of biologically tested compounds or the
number of crystal structures by which a target is represented
in the reference data is not the only factor that determines
how difficult it is for a model to make predictions for a specific
molecule or target.
Given these data biases and challenges, it is clear that aver-
aged performance metrics have limited significance as they
obfuscate the predictive power of a method across queries and
target classes. In fact, the individual characteristics of the tar-
gets and molecules covered by a target prediction model and
by the testing set will determine the measured performance
of a model. It is therefore generally not possible to directly
compare results on model performance obtained from different
studies as these usually use different data for model training and
testing.
To obtain a more realistic representation of the performance
of a target prediction model, a number of measures may be car-
ried out to ameliorate the impact of the data and model biases:
(i) A combination of metrics and methods that are more
robust against the imbalance [10, 11, 55, 56] between
known actives and inactives in the data set (e.g. precision-
recall curve, PR AUC and the MCC) should be used for
model testing. It is also useful to present the confusion
matrices of the performance tests, so that further metrics
may be calculated and used to compare methods.
(ii) For any averaged performance metrics, their minima,
maxima and distributions of values should be reported.
A repeated validation scheme to calculate ROC curves
would be useful in evaluating performance, as an average
ROC curve with its confidence interval can be shown for
assessment.
(iii) Stratified sampling may be applied to construct more
realistic data sets that mimic the real world, for training
and testing. Caution must be exercised to ensure that
oversampling of a class does not result in a model that
is overfit.
(iv) External data should be used for the evaluation of model
performance.
(v) In addition to a standard CV or nested CV, the perfor-
mance of a model should also be evaluated using the var-
ious designed folds to establish performance estimates
under conditions where there is no knowledge of the
query molecule or target (Figure 2) in the training data.
(vi) From a ligand perspective, building on established
concepts in applicability domain research [45, 57–61], a
weighted performance metric should be derived that is
an improvement on the averaged metrics that quantify
generalized performance. Such a metric would account
for the difficulty of predicting the targets of individual
query molecules as a function of the structural similarity
between the query and the training instances (in the
case of structure-based approaches, the similarity to the
closest bound ligand may be used). Graphical approaches
can be powerful tools to visualize such relationships, as
shown by the example in Figure 4. These strategies can
provide a better understanding of a method’s capacity for
inter- and extrapolation and help with the definition of
the applicability domain.
(vii) Performance metrics could also take into account the
complexity of the (known) bioactive chemical space for
the individual targets (in particular, in terms of size and
diversity) as it is indicative of the number of ligand-
binding pockets and subpockets, their size, shape, flexi-
bility and specificity (in terms of pharmacophoric require-
ments).
(viii) From a target perspective, a weighted performance metric
could be used that takes into account the coverage and
complexity of the conformational phase space relevant
to ligand binding. Parameterizing such a performance
metric is a non-trivial task, as in most cases the relevant
conformational phase space remains unknown to a large
extent. As an approximation, tools such as SIENA [62] may
be used to automatically align protein-binding sites and
quantify structural deviations among them.
(ix) The druggability of a target, which is the likelihood of
being able to modulate a target’s activity with a small
molecule [63, 64], may also be an indicator of how diffi-
cult it is, in particular for a docking algorithm, to make
predictions for a specific target. Buried ligand-binding
sites featuring hydrogen bond donors and acceptors are,
for example, typically less challenging to address with
small molecules than shallow hydrophobic interfaces on
the protein surface (as often observed for protein–protein
interaction interfaces) [65]. Docking algorithms show sim-
ilar trends; ligand-binding sites that lack directed inter-
actions or are solvent exposed are more challenging, for
example.
(x) The structural and functional relationships between the
individual targets covered by a model should also be taken
into account. TP predictions of targets that are related
and therefore more challenging to discriminate should
be assigned a higher weight than correct predictions for
targets that are distinct. Likewise, a putative FP prediction
of a target that is in agreement with activity recorded for a
related target should be assigned a lower weight. Putative
FP predictions are cases where compounds are predicted
as active on a particular target, but no bioactivity data
are available to confirm or refute this prediction. Given
the low likelihood of a compound being active on a ran-
dom biomacromolecule, for the purpose of evaluation, the
general assumption made is that the compound is indeed
inactive on that target. However, in the case of closely
related targets there is a good chance that a compound
confirmed to be active on one target is also active on the
other. Ideally, the structural similarity of targets would
be assessed based on the comparison of 3D structures of







niversitetsbiblioteket i Bergen user on 11 February 2020
8 Mathai et al.
Figure 4. Success rates for a target prediction model (e.g. percentage of compounds for which at least one known target was ranked among the top 1, top 3 and top 5
positions) versus the maximum similarity between the individual query compounds and their closest related compounds in the reference data. Such plots are powerful
tools to visualize a method’s capacity for inter- and extrapolation and help with the definition of the applicability domain.
in such comparisons, this is generally not feasible on a
large scale. Instead, the sequence similarity of the protein
domains involved in ligand binding may be used as a
rough indication of the structural similarity of targets as
perceived from a ligand’s perspective.
(xi) While there is no universal gold standard data set, evalu-
ating a model’s performance on benchmarking data sets
will allow for easier comparison among methods.
(xii) In addition to the many strategies involving statistical
means, a critical discussion of representative examples
can be very useful to better understand the scope
and limitations of target prediction models. This could
include comparing the performance of a model for
well-represented versus underrepresented targets or
highlighting the ability of a model to discriminate targets
of a group of related biomacromolecules versus a group
of distinct targets.
Examples of how popular target prediction
methods have been validated
Today, a large number of target prediction models are accessi-
ble via (mostly free) web services [2, 21, 50, 66–69]. The rigor
applied in the evaluation of these methods varies greatly. For
some models, their predictive power has been demonstrated by
a small number of case studies (e.g. ChemMapper [70], Mantra
[71, 72] and TarFisDock [73]). A substantial proportion of models
have been evaluated on larger sets of data (e.g. ChemProt [74],
CSNAP [75], DR. PRODIS [41], HitPick [76], Semantic Link Asso-
ciation Prediction (SLAP) [77], SuperPred [78] and TargetHunter
[79]). Others have undergone systematic statistical validation
by CV (e.g. SPiDER [80] and SwissTargetPrediction [81]). In one
case, namely Similarity Ensemble Approach (SEA) [82], large-
scale experimental evaluations have been reported. We describe
four examples of popular target prediction models that have
undergone some of the most thorough validation experiments
reported so far.
SEA (http://sea.bkslab.org) is an early ligand-based method that
predicts the targets of small molecules based on their similarity
to ligand sets of a reference database [82]. SEA has been tested
through multiple rounds of prospective validation [82, 83]. The
largest study reported so far is by Novartis and included the anal-
ysis of 1241 predicted interactions for 656 approved drugs. Of the
predicted interactions, 348 were retrospectively verified. Further
694 predictions were experimentally tested, of which 48% were
confirmed and 46% were disproved [84]. A number of studies
have since used SEA [85–87] to identify, for example, the targets
of the small molecule ogerin as the adenosine A2A receptor and
of SLV 320, an adenosine A1 antagonist, as an inhibitor of GPCR68
[88]. SEA has undoubtedly had the largest impact and use of
all target prediction methods, and this can be attributed to its
early development and the large-scale experimental testing by
Novartis that is not typically feasible.
SwissTargetPrediction (http://www.swisstargetprediction.ch) is
a ligand-based similarity method that uses both 2D fingerprints
and 3D shape, combined in a logistic regression, to predict the
likely targets of small molecules [81]. SwissTargetPrediction cov-
ers more than 2600 targets from five organisms (human, mouse,
rat, cow and horse) and is arguably one of the most thoroughly
statistically validated target prediction methods in existence
[46]. The method also suggests the orthologs and paralogs of the
predicted biomacromolecules as potential targets. SwissTarget-
Prediction was evaluated by a standard and two designed 10-fold
CV runs. For the 1st designed CV run, molecules with similar
scaffolds were incorporated into the same CV fold to estimate
the performance of the method when the method is used with
structurally distinct ligands [81]. This experiment was repeated
using an additional 2nd filter to group molecules that were
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the probability of a comparison of ligands from the same series
[81]. For all the CV experiments, the folds were created to have
10 times as many negative interactions as positive ones, with
the number of negative interactions supplemented by randomly
pairing ligands and targets with no known positive interactions
together. As expected, the performance of the method was lower
for the designed CV runs (distinct scaffolds ROC AUC 0.979;
distinct scaffolds and assays ROC AUC 0.932) than it was for the
standard CV (ROC AUC 0.994). The effects of ligand properties
(e.g. number of heavy atoms and lipophilicity) on the predic-
tion accuracy were also investigated. In order to estimate the
performance on new molecules, a 2nd external testing set that
was composed of 213 molecules with 346 positive and 278 new
interactions recorded in the consecutive version of the ChEMBL
database. The testing set was expanded with randomly assigned
ligands and targets to ensure that there were five times as many
negative interactions than positive interactions in the testing
set. On these data, the model obtained a ROC AUC of 0.87.
SPiDER (http://modlabcadd.ethz.ch/software/spider/) [80] is a
ligand-based method that utilizes self-organizing maps in
combination with ‘fuzzy’ CATS pharmacophore descriptors [89]
and Molecular Operating Environment (MOE) descriptors [90].
Validation of the method was carried out through a stratified
10-fold CV during which a prediction was considered successful
if all known targets of a query were predicted within a defined
significance threshold. The results from the CV were combined
to calculate the ROC curve and ROC AUC value of 0.92 [80]. The
capacity of SPiDER to predict the biomolecular targets of small
molecules was demonstrated by a number of studies involving
synthetic molecules [80, 91–94] as well as natural products
[92, 95]
SLAP (http://cheminfov.informatics.indiana.edu:8080/slap/) is a
network-based method that uses data from 17 sources and a
semantic network linking the diverse and related data types
(chemical compound, substructure, side effect, chemical ontol-
ogy, target, disease, gene family, tissue, pathway and gene ontol-
ogy) [77]. A chemical compound and a target are considered to
be associated based on the defined path patterns, which include
characteristics such as the length and the type of nodes involved
in the paths between them. To evaluate the model’s perfor-
mance, four testing sets were compiled with known drug–target
pairs from DrugBank and random drug–target pairs (serving as
negative interactions), such that the ratio of positive and nega-
tive interactions was 1:1, 1:4, 1:8 and 1:12. The ROC AUCs (about
0.92 for all sets) and the precision-recall curves were reported
for these tests, along with the performance measures by target
class. SLAP was also evaluated on 23 confirmed drug–target pairs
that were identified with SEA, and it was found that the method
is not capable of identifying cross-boundary targets. In addition,
SLAP was evaluated on 444 drug–target pairs recorded in MATA-
DOR [96] (and not represented in the network) and successfully
identified 170 of these interactions with high confidence.
Conclusions
A plethora of in silico models have become available in recent
years and are increasingly utilized to guide efforts to identify
the biomacromolecular targets of small molecules. While the
modeling approaches have come of age, there is room for further
improvement in the validation of the methods. Ideally, target
prediction methods would be tested in large-scale, prospective
studies, but high expenses in terms of costs and time are, in
general, prohibitive to such efforts. Therefore, developers and
users rely on robust retrospective (statistical) analyses. One of
the most elaborate efforts of retrospective validation was pub-
lished for SwissTargetPrediction, where a standard CV, two CVs
with designed folds and a time-split approach were executed
and analyzed in combination.
One of the most obvious deficits of current approaches to
retrospective validation is their limitation to the global assess-
ment of model performance, which can vary substantially for
individual query molecules and targets as they are represented
in the reference data to different extents. Here, the develop-
ment of weighted scoring functions that account for the chal-
lenges involved in predicting the interaction of specific pairs
of small molecules and biomacromolecules is desirable and
urgently needed. A 2nd major limitation of current retrospective
studies is their lack of comparability, which is a result of a lack
of established, high quality, benchmark data sets and the com-
plexities involved in the validation of target prediction models.
It will take time for both of these issues to be resolved, but
there are several immediate steps that can be taken to obtain
more realistic estimates of model performance. As a minimum
requirement, any target prediction method should undergo a
systematic statistical validation. In particular, it is important for
parameterized models to undergo external validation, and the
results obtained from this test should be discussed with respect
to the results obtained from internal validation. The discussion
of representative test cases is desirable, e.g. the ability of a model
to discriminate bioactivities of small molecules on structurally
distinct targets in contrast to structurally related targets.
We submit that current reports on the performance of mod-
els often miss to convey the implications of the outcomes of
statistical tests on the usefulness of target prediction methods
under real-life conditions. In contrast to the common assump-
tion made during model validation, investigators will most likely
have prior knowledge of some biological properties of a com-
pound. Armed with their expert knowledge they will often be
able to identify false predictions. For the same reason, FP predic-
tions on targets structurally related to the real target of a small
molecule (e.g. predictions of activity on CYP1A2, whereas the
compound actually is an inhibitor of CYP3A4 and not CYP1A2)
can be useful as they may point researchers into the right direc-
tion, even though current validation approaches would com-
monly consider these predictions as false. It is also likely that
investigators will have knowledge of several structurally related
compounds exhibiting the same kind of biological activity rather
than a singleton. By using multiple structurally related com-
pounds as queries the signal-to-noise ratio can be improved.
On the downside, in a real-life scenario, compounds of interest
are likely to be more distant to the training data than the
average compound of the testing set, which makes observing the
applicability domain of a model an important issue.
Overall, we believe, and the recent reports in the literature
show, that in silico models have become powerful tools to aid
the identification of the mode of action of small molecules. We
should not expect target prediction methods to generally be able
to correctly rank the targets of a compound of interest among the
top 1 or top 3 out of several hundreds or thousands of biomacro-
molecules. However, we are on a good track of developing models
that are able to provide valuable guidance to experimentalists in
their efforts to confirm the relevant targets of small molecules
and to point out if a compound of interest is outside of the appli-
cability domain of a model. This is a qualitative improvement to
the challenging task of mode of action identification, and the
increasing availability of chemical and biological data will lead
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Key Points
• In silico models have become important and powerful
tools to efforts to identify the biomacromolecular tar-
gets of small molecules.
• Commonly followed strategies in assessing the per-
formance of target prediction approaches do not ade-
quately account for the heavy biases present in the
chemical and biological data utilized for training and
testing.
• A number of immediate measures can be taken to
obtain more realistic estimates of the performance of
target prediction models.
• New metrics that weigh the difficulty of individual
predictions are urgently needed, as are benchmark data
sets enabling the comparative performance analysis of
target prediction methods.
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